Abstract
A prospective randomised multicentre clinical study was undertaken for 2 years and 3 months from November 1982, with the aim of examining the significance of using a combination of ftorafur (FT) and tamoxifen (TAM) for post-operative adjuvant therapy of breast cancer. Patients had either stage II or stage IIIa disease, were age 75 or below and had undergone radical mastectomy. Patients were divided into two groups and received one of the following treatment protocols: treatment A, intravenous administration of doxorubicin (DOX), 20 mg on the day of surgery and 10 mg the next day, followed by oral FT 50 mg day-1 for 2 years from the 14th day; treatment B, the same pattern of DOX administration for the first 2 days, followed by a combined therapy of FT and TAM 20 mg day-1 for 2 years. The number of patients was 546 (treatment A 274 and treatment B 272), of whom 34 (6%) were ineligible. The remaining 512 patients (treatment A 254 and treatment B 258) were followed up for 5 years for analysis. Significantly higher 5 year disease-free rate and 5 year survival rates were observed with treatment B compared with treatment A. When seen in terms of background factors, node-positive patients appeared to derive more benefit from tamoxifen than node-negative patients, but the oestrogen receptor-negative and premenopausal subgroups appeared to derive about the same benefit as those who were oestrogen receptor positive and post-menopausal. Indeed, survival in the premenopausal group was significantly better with tamoxifen (P = 0.04). No increase in side-effects was seen by combining TAM with FT. The study results demonstrate that concomitant administration of FT and TAM is better than FT alone for post-operative adjuvant therapy for breast cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hubay C. A., Gordon N. H., Crowe J. P., Guyton S. P., Pearson O. H., Marshall J. S., Mansour E. G., Hermann R. E., Jones J. C., Flynn W. J. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up. Surgery. 1984 Jul;96(1):61–72. [PubMed] [Google Scholar]
- Ingle J. N., Everson L. K., Wieand H. S., Cullinan S. A., Wold L. E., Hagen J. B., Martin J. K., Krook J. E., Fitzgibbons R. G., Foley J. F. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer. 1989 Apr 1;63(7):1257–1264. doi: 10.1002/1097-0142(19890401)63:7<1257::aid-cncr2820630705>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
- Mauriac L., Durand M., Chauvergne J., Bonichon F., Avril A., Mage P., Dilhuydy M. H., Le Treut A., Wafflart J., Marée D. Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre. Breast Cancer Res Treat. 1988 May;11(2):179–186. doi: 10.1007/BF01805842. [DOI] [PubMed] [Google Scholar]
- Osborne C. K., Boldt D. H., Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984 Apr;44(4):1433–1439. [PubMed] [Google Scholar]
- Tormey D. C., Gray R., Gilchrist K., Grage T., Carbone P. P., Wolter J., Woll J. E., Cummings F. J. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer. 1990 Jan 15;65(2):200–206. doi: 10.1002/1097-0142(19900115)65:2<200::aid-cncr2820650203>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
- Wada T., Koyama H., Nishizawa Y., Takahashi Y., Fukuda I., Iwanaga T., Terasawa T. [Chemo-endocrine therapy for advanced breast cancer--a combined treatment with tamoxifen and FT 207-- (author's transl)]. Nihon Gan Chiryo Gakkai Shi. 1981 Feb 20;16(1):51–55. [PubMed] [Google Scholar]